Comparison of Ferucarbotran-Enhanced MRI and Triple-Phase MDCT for the Detection of Hepatocellular Carcinoma in Advanced Liver CirrhosisComparison of Ferucarbotran-Enhanced MRI and Triple-Phase MDCT for the Detection of Hepatocellular Carcinoma in Advanced Liver Cirrhosis
- Other Titles
- Comparison of Ferucarbotran-Enhanced MRI and Triple-Phase MDCT for the Detection of Hepatocellular Carcinoma in Advanced Liver Cirrhosis
- Authors
- 전용환; 김승훈; 최동일; 김민주; 김삼수; 이지원; 한헌; 이종미
- Issue Date
- 2008
- Publisher
- 대한영상의학회
- Keywords
- Carcinoma; hepatocellular
Liver cirrhosis
Magnetic resonance (MR)
Tomography; spiral computed
Ferumoxides; Carcinoma; hepatocellular
Liver cirrhosis
Magnetic resonance (MR)
Tomography; spiral computed
Ferumoxides
- Citation
- 대한영상의학회지, v.58, no.1, pp.53 - 63
- Indexed
- KCI
- Journal Title
- 대한영상의학회지
- Volume
- 58
- Number
- 1
- Start Page
- 53
- End Page
- 63
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/124263
- ISSN
- 1738-2637
- Abstract
- Purpose: To compare the diagnostic performance of ferucarbotran-enhanced MRI at 1.5-T with triple-phase multidetector-row helical CT (MDCT) to detect hepatocellular carcinoma in patients with advanced liver cirrhosis.
Materials and Methods: Twenty patients with advanced liver cirrhosis (Child's class B:C = 8:12) underwent ferucarbotran-enhanced MRI and triple-phase MDCT prior to liver transplantation. The mean time interval between the two imaging techniques was 18 days (range, 1-35 days). Three radiologists independently reviewed both images on a lesion-by-lesion basis and interpreted them for comparison with the pathologic findings of the explanted livers. As well, the sensitivity and an alternative-free response receiver operating characteristics (ROC) analysis was used to evaluate the diagnostic performance of each technique.
Results: The mean area under the ROC curve (Az) was significantly higher for the triple-phase MDCT (0.766) compared to the ferucarbotran-enhanced MRI (0.675) (p < 0.001). Similarly, the mean sensitivity of the triple-phase MDCT (60.3%) exceeded the ferucarbotran-enhanced MRI (43.1%). The results indicate that the triple-phase MDCT provides significantly greater mean sensitivity than the ferucarbotran-enhanced MRI (p < 0.001).
Conclusion: The triple-phase MDCT provided a better diagnostic performance and higher sensitivity than the ferucarbotran-enhanced MRI for the detection of hepatocellular carcinomas in patients with advanced liver cirrhosis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.